Merck signs exclusive global license with SciBrunch for KRAS G12D drug SPR2015 in USD 2.13 billion deal

Bitget2026/09/28 10:46

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Merck signed an exclusive global license with SciBrunch Therapeutics for SPR2015, a preclinical oral KRAS G12D (ON) inhibitor.
Deal grants worldwide rights to develop, manufacture, commercialize SPR2015.
SciBrunch to receive USD 400 million upfront.
Milestone payments could lift total potential deal value to USD 2.13 billion across multiple indications.
Merck expects a USD 400 million pre-tax charge in Q3 2026, about USD 0.13 per share.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck & Co. Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609280645BIZWIRE_USPR_____20260928_BW125137) on September 28, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Merck signs exclusive global license with SciBrunch for KRAS G12D drug SPR2015 in USD 2.13 billion deal

You may also like

Crypto prices